Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




New Online Toolkit to Standardize Measures and Protocols in Genetic Research

By LabMedica International staff writers
Posted on 06 May 2009
Scientists who conduct genetic studies will now have a new set of tools to refine estimates of disease risk and extend the findings of one study to other studies or across population groups. More...
The tools, a set of standard measures and research protocols, are part of a U.S. effort designed to accelerate understanding of the complicated genetic and environmental factors associated with cancer, heart disease, depression, and many other common diseases.

Collectively called the PhenX Toolkit, the measures and protocols were developed as part of the three-year collaborative research effort, called PhenX (pronounced "phoenix"), which is a combination of the words phenotype and exposures. The effort, being led by the independent, nonprofit research organization RTI International (Research Triangle Park, NC, USA), is funded by the U.S. National Institutes of Health's National Human Genome Research Institute (Bethesda, MD, USA). "The use of standard measures is vital to furthering our knowledge of the many complex relationships between genetics, environmental factors, and common diseases," said Carol M. Hamilton, Ph.D., director of bioinformatics at RTI and the project's lead investigator.

The initial release of the toolkit includes the high-priority measures selected by panels with expertise in demographics; anthropometrics (measures of body size and proportion); and alcohol, tobacco, and other substances. Experts in the cardiovascular field, as well as those with expertise in nutrition and dietary supplements, are currently working to identify measures that will be added to the toolkit within the next few months.

In all, the toolkit is expected to include about 300 high-priority measures covering a range of conditions and exposures relevant to common diseases. Users of the toolkit can browse measures and protocols, search using keywords, generate reports, and select measures for use in their studies. The use of consensus measures in their studies allows researchers to pool study results, increase the capability to identify associations, and facilitate comparison of different studies.

The initial measures and protocols were developed over the past 12 months by three expert panels, with contributions from more than 100 scientists from diverse scientific and health disciplines who participated or served as reviewers.

RTI International is one of the world's leading research institutes, focused on improving the human condition by turning knowledge into practice. The company's staff of more than 2,800 provides research and technical expertise to governments and businesses in more than 40 countries in the areas of health and pharmaceuticals, education and training, surveys and statistics, advanced technology, international development, economic and social policy, energy and the environment, and laboratory and chemistry services.

Related Links:

RTI International



Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Verification Panels for Assay Development & QC
Seroconversion Panels
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
Blood Glucose Reference Analyzer
Nova Primary
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.